

**CRO Communiqué**  
**Keeping you informed about CRO progress**  
**October 2011**

**Top Enrolling Physicians for September 2011**

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Carlson	7	.6	1	1.6
Dr. Tiriveedhi	3	2.6	1	3.6
Dr. Bonebrake	3	2	.5	2.5
Dr. Gillette	1	1	0	1
Dr. Holden	1	1	0	1

CRO added 9.7 total credits to our yearly NCI target this month: 7.2 treatment credits and 2.5 cancer control. To be on track to meet this year's NCI target credits we need to be at 40 treatment and 20 cancer control credits. We currently have 38.5 treatment and 18 cancer control credits so we are just a bit behind, needing 1.5 treatment and 2 cancer control credits to be on target. Thanks to all our investigators for considering clinical trials for your patients.

**Steering Committee Meeting on October 3, 2011**

This coming Monday, October 3, 2011, is our CRO Steering Committee meeting. Dr. Ravi Vij from Washington University School of Medicine in St. Louis will be with us to speak on multiple myeloma. The event will be at Flame Restaurant, 314 W. Walnut, Springfield at 6:15pm. Please RSVP to 417-269-4520.

**Annual CCOP PI and Administrators Meeting**

Dr. Carolla and Marilyn Bauer attended the annual Community Clinical Oncology Program's PI and Administrators meeting on September 26 and 27 in Bethesda, MD. The CCOP program is being transformed following the Institute of Medicine's recommendations in April 2010 that the eleven cooperative groups be consolidated into five groups with one of these being a pediatric group. NCCTG, CALGB and ACOSOG are leading the mergers and will be known as the Alliance. ECOG and ACRIN will be joining forces as will be GOG, NSABP and RTOG. SWOG will stand alone. The 5<sup>th</sup> group is Children's Oncology Group, COG, which is the unity of several children's oncology groups in past years. The consolidation of research bases will result in operational efficiencies including consolidation of forms, standardization of imaging, sharing of data, and acceleration in the activation timelines for clinical trials to mention just a few.

**Study Profile**

DMP-1 "A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer" is our study to profile this month. The primary objective is to describe the influence of social, environmental, and psychological factors (sociality of medication intake, life-events, understanding of prevention, clinical situation) on the decision of women at risk for breast cancer as to whether or not to take chemoprevention agents. The participant must have been identified as being at increased risk for breast cancer as determined by the doctor/HCP. During the participant's counseling session, breast cancer risk and the use of SERM, (selective estrogen receptor modulator) for breast cancer risk reduction must have been discussed, as reported by the doctor/HCP who conducted the session. Participants at all sites will complete two questionnaires.

**Dr. Carlson NCI's Top Enroller**

Dr. Jay Carlson was recognized as the highest accruing investigator for treatment and treatment plus cancer control combined from his work at the Iowa CCOP during NCI grant year 2010-2011. This recognition was announced at the CCOP PI and Administrators meeting earlier this week. Congratulations to Dr. Carlson!

**New CRO Staff**

Sharon Brown RN joined CRO as a PRN research nurse on September 19<sup>th</sup>. Sharon previously worked as a NCI research nurse at Freeman in Joplin. Amber Pierce RN will be joining us as a full-time research nurse in mid-October. Amber has been in oncology for 10 years, most recently as the Assistant Nurse Manager on 500 West at Cox. We are delighted to have both ladies on our CRO team.

## **New Studies Approved in September 2011**

### **Opened at Cox and St. John's**

**MDA 2009-0288** POWER Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients

**NSABP DMP-1** A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer

### **Studies Permanently Closed to Enrollment at Cox & St. John's in July 2011**

**GOG-0126T** A Phase II Evaluation of Belinostat and Carboplatin in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

**SWOG E1905** A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor Entinostat for the treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia

**SWOG S0904** Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma